CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-24.79%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.67B
AUM Growth
+$1.67B
(-13%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
6.35%
Top 10 Holdings %
Top 10 Hldgs %
63.16%
Holding
36
New
8
Increased
12
Reduced
6
Closed
7
Top Buys
| 1 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$130M |
| 2 |
GSK
GSK
|
$114M |
| 3 |
AbbVie
ABBV
|
$91.4M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$69.6M |
| 5 |
Ventas
VTR
|
$67M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$191M |
| 2 |
Gilead Sciences
GILD
|
$97.5M |
| 3 |
DaVita
DVA
|
$75M |
| 4 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$69.9M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$58M |
Sector Composition
| 1 | Healthcare | 85.42% |
| 2 | Technology | 7.76% |
| 3 | Real Estate | 5.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBIO
26
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $7.98M | 0.48% | 3,500,000 | – | – |
|
27
Pacific Biosciences
PACB
$393M
| $7.65M | 0.46% | +2,500,000 | New | +$7.65M |
|
28
Sutro Biopharma
STRO
$72.7M
| $6.12M | 0.37% | 600,000 | – | – |
|
|
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
| $1.7M | 0.1% | +33,630 | New | +$1.7M |
|
|
30
DaVita
DVA
$9.85B
| – | – | -1,000,000 | Closed | -$75M |
|
|
31
Gilead Sciences
GILD
$140B
| – | – | -1,500,000 | Closed | -$97.5M |
|
32
Pediatrix Medical
MD
$1.5B
| – | – | -790,000 | Closed | -$22M |
|
33
Teva Pharmaceuticals
TEVA
$21.1B
| – | – | -2,000,000 | Closed | -$19.6M |
|
|
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – | -730,000 | Closed | -$58M |
|
|
AGN
35
DELISTED
Allergan plc
AGN
| – | – | -1,000,000 | Closed | -$191M |
|
|
THOR
36
DELISTED
Synthorx, Inc. Common Stock
THOR
| – | – | -1,000,000 | Closed | -$69.9M |
|